Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. Guidelines by topic
  4. Genitourinary Cancers
  5. Bladder Cancer

eUpdate – Advanced Urothelial Carcinoma Treatment Recommendations

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

Ann Oncol. 2024;35(6):485-490
Powles T, Bellmunt J, Comperat E, et al., on behalf of the ESMO Guidelines Committee

  • This ESMO Clinical Practice Guideline eUpdate addresses developments in first-line therapy in advanced urothelial carcinoma.
  • EV+P is the new standard of care in first-line advanced urothelial carcinoma.
  • Nivolumab–cisplatin–gemcitabine or platinum-based ChT and maintenance avelumab are alternatives if EV+P is not possible.

Related items

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.